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Generation of human papillomavirus type 11 and 18 genomes encoding hemagglutinin 
epitope-tagged E1 proteins 
Human papillomaviruses (HPVs) are associated with numerous disorders ranging from warts 
to cancerous diseases. Although vaccination against several types of HPVs is available, a 
number of HPV-associated cancers remains stable. Therefore, studies on HPV are required for 
developing novel HPV-targeting drugs. Encoded by HPV E1 helicase is absolutely required for 
HPV replication. Therefore, it is a good target for developing antiviral drugs.  
This project aimed at generating HPV11 and HPV18 genomes encoding human influenza 
hemagglutinin (HA)-tagged E1 proteins with the further goal to test their replication ability in 
U2OS cell line. The study revealed that HA-tagged E1 proteins maintained the replication of 
the modified HPV genomes at levels similar to wild-type HPVs (wtHPVs). Thus, this study 
opens possibilities to investigate HPV11 and HPV18 endogenous E1 proteins using highly 
specific antibodies against HA epitope and introduces a less expensive and universal method to 
study E1-associated processes in the HPV life cycle. 
Keywords: E1 protein, HA-tag, human papillomavirus (HPV), replication 
CERCS code: B230 Microbiology, bacteriology, virology, mycology 
Inimese papilloomiviiruse tüüp 11 ja 18 hemaglutiniin märgisega E1 lugemisraami 
kodeerivate genoomide kloneerimine ja analüüs 
Inimese papillomaviirused (HPV) on seotud erinevate terviseprobleemidega alates tüükadest ja 
lõpetades pahaloomuliste kasvajatega. Kuigi vaktsineerimine mõne HPV vastu on juba olemas, 
HPV-dega seotud kasvajate hulk oluliselt ei vähene. Seetõttu on vajalik arendada uudseid HPV-
de vastu ravimeid. Kodeeritud HPV genoomis E1 helikaas on vajalik HPV replikatsiooniks. 
Seetõttu, E1 on hea sihtmärk viirusevastaste ravimite arendamiseks.  
Selle uuringu eesmärk oli luua HPV11 ja HPV18 genoomid, mis kodeerivad E1 valgu koos 
inimese gripi viiruse hemagglutiniin (HA)-märgisega ning nende replikatsiooni võimet 
kontrollimine U2OS rakku liinis. Uuringu tulemused näitasid, et muteeritud HPV genoomid 
replitseerusid sarnaselt metsik-tüüpi HPV-dega. Seega, see uuring avab võimalusi uurida 
HPV11 ja HPV18 endogeense E1 valguga seotud protsesse kasutades spetsiifilisi antikehi HA-
märgise vastu. 
Märksõnad: E1 valk, inimese papillomaviirus (HPV), HA-märgis, replikatsioon 
CERCS kood: B230 Mikrobioloogia, bakterioloogia, viroloogia, mükoloogia 
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LIST OF ABBREVIATIONS 
ara-BAD – Escherichia coli operon that encodes proteins required for the metabolism of L–
arabinose under control of PBAD L–arabinose inducible promotor  
ATM – ataxia-telangiectasia mutated kinase signaling pathway  
ATR – ATM and Rad50 dependent kinase signaling pathway 
BPV1 – bovine papillomavirus type 1  
Cdk2 – cyclin-dependent kinase 2 
DBD – DNA-binding domain 
DDR – DNA damage response pathways  
DH complex – E1 double-hexamer complex 
dsDNA – double-stranded DNA  
DSB – DNA double-strand breaks  
DT complex – E1 double-trimer complex 
E region – early proteins encoding genomic region 
E1BS – E1-binding site in the ori 
E1-HA HPV – HPV with HA-tag encoding sequence cloned into E1 ORF  
E2F – transcription factors that regulate entry into S-phase 
E6-AP – E6-associated protein  
EV – rare hereditary disorder Epidermodysplasia verruciformis 
HA-tag - human influenza hemagglutinin peptide 
HD – C-terminal helicase domain of E1  
HNC – head and neck cancer  
HPV – human papillomavirus  
L region – late proteins encoding genomic region 
LT – large T-antigen protein 
MCS – multiple cloning site  
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NES – Crm1-dependent nuclear export signal  
NGM – normal growth medium  
NLS – nuclear localization signal  
OBD – origin-binding domain of E1 
ori – origin of replication 
ORF – open reading frame 
p53 – tumor suppressor protein 53 
PAE – early polyadenylation site 
PAL – late polyadenylation site 
PaVE – Papillomavirus Episteme database 
PCNA – proliferating cell nuclear antigen 
PCR – polymerase chain reaction 
Pol α-prim – DNA polymerase α-primase complex 
pRb – retinoblastoma tumor suppressor protein 
PVs – Papillomaviruses  
RPA – replication protein A 
RT – room temperature 
RFC – replication factor C  
ssDNA – single-stranded DNA  
SSE – stratified squamous epithelium  
SUMO – small ubiquitin-like modifier  
SV40 – Simian virus 40  
TA domain – E2 N-terminal transactivation domain 
Topo I – topoisomerase I  
URR – noncoding upstream regulatory region  
VLPs – virus-like particles  
wtHPV – wild-type HPV  
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INTRODUCTION 
Most of sexually active people have human papillomavirus (HPV) infection during their life 
(Bucchi et al., 2016). Papillomaviruses (PVs) are widespread in human population, and they 
are not only pathogenic viruses, but also present in normal skin microbiota (Hazard et al., 2007). 
They infect epithelial keratinocytes through microinjuries and can persist in skin or mucosa for 
a long time. The main reason to study HPVs more vigorously is their association with cancerous 
deceases including anogenital cancers and oropharynx or other head- and neck-associated 
tumors. For example, the largest part of cervical carcinoma shares the presence of HPV genomic 
DNA (Adams et al., 2014). Nowadays, vaccination is the main direction to prevent HPV 
infection (Hancock et al., 2018). On the other hand, HPV-associated cancers cannot be cured 
with medicines or vaccination, so only surgical operation or other invasive methods can help. 
Therefore, functional drugs against HPV infections are needed. Better understanding of the 
HPV life cycle can help in discovering new methods for prevention or treatment of HPV-
associated diseases.  
HPV usually encodes at least eight functionally different proteins. Among them, the E1 protein 
is one of the best targets for the development of antiviral drugs. E1 has various functions in the 
HPV infection cycle, but the main E1 function is participation in HPV DNA replication 
(Bergvall et al., 2013). E1 and E2 are the only viral proteins that are necessary and sufficient 
for HPV replication, and inhibiting their activities is a good possibility to inhibit HPV infection 
at all (Yang et al., 1993). Detection and purification of the E1 protein in laboratory systems is 
a huge problem, and therefore studies on E1-dependent processes in HPV replication and 
development of new E1-targeting drugs are also complicated.  
The aim of this study is to create a new tool suitable for studies on the E1 protein more 
sensitively and directionally. The present thesis contains two parts. The first part is the literature 
overview where HPV types, viral life cycle and models for studying it, HPV protein functions, 
and E1 protein characteristics are reviewed in details. The experimental part contains the 
description of the generation of HA-tag-containing HPV types 11 and 18 constructs and the 
verification of their replication status in the U2OS cell line in comparison with wild-type HPV 
(wtHPV) types 11 and 18. This study was performed in the molecular virology research group, 
Institute of Technology, University of Tartu. 
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1. LITERATURE OVERVIEW 
1.1 Papillomaviridae 
Papillomaviruses (PVs) are species-specific, double-stranded DNA (dsDNA) small viruses that 
infect epithelial keratinocytes. Their icosahedral, non-enveloped virion contains a circular 
genome approximately 8 kbp in length, which is packed into nucleosomes by cellular histones 
and usually encodes 8 genes (Favre et al., 1977). PVs infect a wide range of vertebrate species 
including majority of mammals, but also reptiles and birds (de Villiers et al., 2004). Based on 
the structure of the skin, the most suitable hosts for PVs are mammals, including humans (Bravo 
et al., 2010). 
The classification of different types of PVs is based on the nucleotide sequence of the L1 major 
capsid protein open reading frame (ORF) since it is one of the most conserved sequences in the 
PV genome. When the virus L1 ORF differs at least 10% from the known types of PVs, the 
virus is classified as a new type (de Villiers et al., 2004). At present, over 400 PVs belonging 
to more than 40 different genuses of the Papillomaviridae family are identified, and due to 
novel methods of identification, the number of described viruses is continuously increasing 
(Figure 1). PVs are listed in the fast-growing Papillomavirus Episteme (PaVE) database [1].  
1.2 Human Papillomaviruses 
Human Papillomaviruses (HPVs) are widespread pathogenic DNA viruses. HPVs are 
phylogenetically distributed into five different families: alpha- (α), beta- (β), gamma- (γ), mu- 
(μ), and nupapillomaviruses (ν) (de Villiers et al., 2004) (Figure 1). Currently, more than 200 
different types of HPVs are described [1]. 
HPVs are divided into two groups, depending on their ability to infect cutaneous or mucosal 
epithelium. Cutaneous and mucosal HPVs are further subdivided into high- and low-risk types 
according to their potential to induce malignant progression of the lesion in the host organism 
(Mistry et al., 2008). Low-risk HPVs produce benign hyperkeratotic lesions (warts and 
condylomas) with a low probability of developing cancer (Egawa & Doorbar, 2017). In 
contrast, high-risk types are capable of inducing malignant tumors (Bucchi et al., 2016). 
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Figure 1. HPVs belong to alpha- (α), beta- (β), gamma- (γ), mu- (μ), and nupapillomaviruses 
(ν). The figure is adapted from the ICTV database [2]. 
1.2.1 Cutaneous HPVs 
Cutaneous HPVs belonging to β-, γ-, ν-, µ-, and some α-papillomaviruses infect skin (Bzhalava 
et al., 2013). Low-risk HPVs are well adapted to the host, generally cause asymptomatic 
infections, and can be found in healthy skin. Therefore, they are considered as a part of the 
normal microbiota of the human skin (e.g., HPV12 or HPV20) (Hazard et al., 2007). However, 
some skin HPVs can cause benign epithelial growths, such as warts or papillomas, which 
disappear after some time due to the adaptive immune system (Amador-Molina et al., 2013).  
Nevertheless, high-risk cutaneous HPVs (e.g., HPV3 or HPV10) can induce malignant tumors 
in immunosuppressed individuals (Reusser et al., 2015). For instance, in the case of an 
extremely rare autosomal recessive hereditary disorder Epidermodysplasia verruciformis (EV), 
also known as treeman syndrome, the immune system is not able to eliminate HPV infection 
(e.g., HPV5), and primary lesions like palules and macules form on the skin and can progress 
to cutaneous carcinomas over time (Leiding & Holland, 2012). 
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1.2.2 Mucosal HPVs 
Mucosal HPVs belong to the genus α-papillomaviruses (Bzhalava et al., 2013). Some mucosal 
HPVs belong to high-risk types because of their oncogenic potential (HPV types 16, 18 or 33), 
and therefore, they are the most studied PVs. Mucosal HPVs are mostly associated with 
anogenital area cancers, but also with upper respiratory tract, oral cavity, and other head and 
neck tumors. For instance, high-risk mucosal HPV16 prevails in HPV-associated head and neck 
squamous cell carcinomas and also is found in cervical carcinomas (50% of cases). HPV18 is 
another HPV most commonly identified in cervical carcinomas (20% of cases) (Adams et al., 
2014).  
Low-risk mucosal HPVs (e.g. HPV6 and HPV11) produce benign tumorous warts, called 
papillomas (condylomas in the anogenital area), which in most cases resolves spontaneously, 
and their progression to cancer is not generally observed in healthy people (Chow & Broker, 
2013). Some HPVs are classified as probable high-risk types (e.g., HPV types 26, 53 and 66) 
(Bucchi et al., 2016). High-risk HPV18 and low-risk HPV11 studied in the present work belong 
to mucosal α-papillomaviruses. 
1.2.3 Prevention or treatment of HPV infection  
HPVs as the most common sexually transmitted viral pathogens cause approximately 5% of the 
global cancer burden (Egawa & Doorbar, 2017). HPVs are mostly associated with cervical 
cancer and other anogenital cancers including anal, vulvar, and penile cancers (Chabeda et al., 
2018). Although the main route of HPV infection is sexual contact, nonsexual transmission can 
occur from mother to child prenatally or perinatally (Lee et al., 2013). Recently, high-risk HPV 
infections were found to be also associated with head and neck cancers (HNCs), especially in 
the oropharynx (Ang et al., 2011). Approximately 98% of cervical carcinomas and at least 25% 
of HNCs share the presence of HPV DNA (Adams et al., 2014). In developed countries, cervical 
cancer screening allows early detection of diseases resulting in overall decrease of cervical 
cancer mortality. Unfortunately, cervical cancer is much more common in developing 
countries. Therefore, it is the second leading cause of cancer-related death in women in the 
developing world (Ladner et al., 2016).  
Now, there are three HPV vaccines approved to use. The Gardasil induces antibody production 
against high-risk HPV16 and HPV18 and protects against low-risk HPV6 and HPV11. Cervarix 
vaccines are targeted only against HPV16 and HPV18. Recently, Gardasil 9 or nine-valent 
vaccine against HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58 has been introduced to the market. 
Available vaccines are successful, but there are lots of additional high-risk HPV types 
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associated with about 30% of cervical cancers (Hancock et al., 2018). Besides, vaccination does 
not cure people already harboring HPV infection. Therefore, studies of HPV molecular biology 
and life cycle are essential for HPV-associated cancer prevention and treatment (Winters et al., 
2006). 
1.3 HPV infection cycle 
HPVs infect stratified squamous epithelium (SSE) (Kajitani et al., 2012). This epithelium is 
subdivided into two types: keratinized SSE (e.g., epidermis of the skin) and nonkeratinized SSE 
(e.g., mucosa of vagina or anal canal). Accordingly, HPVs are also divided into cutaneous and 
mucosal types.  
The main part of all SSEs is keratinocytes at various stages of differentiation. HPVs infect 
highly mitotic basal keratinocyte stem cells located in the basal layer of SSE because of their 
ability to accomplish the cycle of dividing and differentiation (Longworth & Laimins, 2004). 
These cells divide asymmetrically: one daughter cell remains in the basal layer as a stem cell 
of the epithelium; the other moves to the upper layers undergoing the programmed 
differentiation. The HPV infection cycle is roughly connected to differentiation of 
keratinocytes.  
HPV enters the host cell in the basal layer through the epithelial microinjuries. During the life 
cycle, HPV undergoes three different replication phases that reflect the stages of the infection 
(Figure 2) (McBride, 2008). During the first stage named transient initial amplification, HPV 
copy number reaches about 50–100 per cell (Kadaja et al., 2009). The second stage is stable 
maintenance replication during latent infection, and the HPV copy number remains stable. 
These phases occur in the epithelial basal layer (McBride, 2008). The last step is vegetative 
amplification, which occurs during the productive phase of the infection, when the HPV amount 
grows to more than 1000 copies per cell. This process takes place in terminally differentiated 
keratinocytes when virions are starting to form (Kadaja et al., 2009). 
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Figure 2. Representation of the HPV life cycle. HPV enters the cell and amplifies itself in the 
basal layer to the stable state. During programmed differentiation of keratinocytes, HPV 
amplifies to around 1000 copies per cell and eventually forms virions that leave the terminally 
differentiated cell (Ustav jr., 2016.). 
1.4 HPV molecular biology 
1.4.1 HPV genomic organization 
The genome organization of different HPVs is generally similar. A schematic representation of 
HPV11 and HPV18 genomes is shown in Figure 3. The HPV genome is an approximately 8 
kbp dsDNA circular molecule with open reading frames (ORFs) located on a single DNA strand 
(Graham, 2010). The genome can be divided into two coding regions: an early (E) and a late 
(L) regions and a noncoding upstream regulatory region (URR), located between them. The 
transcripts from the E region are produced during almost all stages of the viral life cycle until 
packaging of the genome in the upper layers of epithelium. Expression of late ORFs encoding 
L1 and L2 capsid proteins occurs only at the end of the virus infection cycle when the viral 
genome has to be packed (Graham, 2010). The noncoding URR region contains binding sites 
for the main viral regulatory protein (E2) and cellular transcription factors, the origin of the 
replication (ori), and the early and late promoters (McBride, 2008). In some HPVs (e.g., HPV11 
or HPV16), the late promoter is located in the E7 ORF (Grassmann et al., 1996). There are also 
early (PAE) and late (PAL) polyadenylation sites, in which the synthesis of early or late 
transcripts, respectively, ends (Graham, 2010). As PV mRNAs are polycistronic, it is difficult 
to identify all transcripts that might have a role in the viral life cycle (Wang et al., 2011). 
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Figure 3. Schematic representation of HPV11 and HPV18 genomes. HPV genome can be 
divided into three different regions: early ORFs (E1, E2, E4, E5, E6, and E7) indicated by green, 
late ORFs (L1 and L2) shown in blue, and URR region (yellow). Also HPV encodes some 
truncated forms of proteins using different ORFs (E1^E4 and E8^E2C) (orange and pink). The 
URR contains different regulatory sequences and binding sites for viral and cellular proteins. 
The figure is adapted from the PaVE database [1]. 
1.4.2 Overview of viral proteins 
HPV pre-mRNAs transcribed from the early region are alternatively spliced producing a variety 
of functional mRNAs that encode proteins E1, E1^E4, E2, E8^E2C, E5, E6, and E7. These 
proteins are required for HPV replication, transcription, genome segregation, and modulation 
of the host cell cycle (Graham, 2010). The L1 and L2 proteins, synthesized from the late coding 
region, form the virus capsid and have a role in HPV interactions with a host cell (Aksoy et al., 
2017). 
1.4.2.1 Early region proteins 
The E1 protein (approximately 68 kDa) is absolutely needed for replication of the viral genome 
(Blitz & Laimins, 1991). It is the only enzyme encoded by HPVs (Yang et al., 1993). The E1 
proteins of HPV11 and HPV18 are in the focus of this thesis. Therefore, the structure of E1 and 
its role in the HPV life cycle are discussed in more detail in chapters 1.5 and 1.6 of this thesis. 
Fusion protein E1^E4 is considered to be an early protein, but during the HPV life cycle, 
E1^E4 generally becomes detectable at the beginning of the late stages of the infection cycle 
(Wilson et al., 2007). In the early stages of the infection, the synthesis of the E1^E4 protein 
occurs at a very low level. Nevertheless, the E1^E4 protein is believed to be implicitly involved 
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in replication and transcription of viral DNA via binding and stabilizing the E2 protein (Davy 
et al., 2009). Also, it has been suggested that the E1^E4 protein serves to optimize the exit of 
virions from cells in the upper epithelial layers (Doorbar, 2013). In addition, the E1^E4 protein 
is capable to induce a cell cycle arrest in G2 phase and to target the host cell to apoptosis (Davy 
et al., 2002). 
The full-length E2 protein is a transcription factor consisting of two domains linked together 
by a linker sequence called the hinge region. The E2 C-terminal region is a DNA-binding 
domain (DBD). On the other hand, the N-terminal region forms a transactivation (TA) domain 
(McBride, 2013). E2 is a multifunctional protein that is involved in various HPV life cycle 
processes. E2 interacts with different cellular proteins and plays a key role in controlling the 
transcription of viral proteins (Graham, 2016). Transcriptional activation or repression depends 
on the binding affinity of the full-length E2 protein for its binding sites (ACCGN4CGGT 
motifs) located in the URR region (Võsa et al., 2012). At lower concentrations, the E2 protein 
acts as a transcriptional activator, higher concentrations of E2 lead to repression of the viral 
DNA transcription (Bouvard et al., 1994). The E2 protein also plays an important role in 
initiation of viral DNA replication and segregation of HPV genomes in mitotic cells (McBride, 
2013). The E2 protein of high-risk HPVs is capable of activating apoptosis in host cells, which 
can be important in a context of releasing viral particles in environment (Singh et al., 2016). 
Also, some studies indicated that the E2 protein enhances packaging of HPV genomes in virions 
through interactions with the L2 protein (Zhao et al., 2000). Disruption of E2 during the process 
of HPV DNA integration into the host cell genome may also lead to increased oncogenic 
potential of the viral E5, E6, and E7 proteins (Williams et al., 2011).  
All PVs have been shown to express an E8^E2C (or equivalent) inhibitor protein that is 
encoded by a truncated E2 transcript (Straub et al., 2014). The E8^E2C protein lacks a TA 
domain but possesses the E8 ORF-encoded sequence, which is located in the E1 ORF, a C-
terminal DBD and a linker-region of E2 (McBride, 2013). E8^E2C is the only protein that can 
compete with full-length E2 for binding sites in the URR region and repress early transcription 
and replication. Knock-down of E8 ORF results in increased copy numbers of the HPV genome. 
Also E8^E2C can form an inactive heterodimeric form with the E2 protein repressing 
transcription and replication (Straub et al., 2014).  
Generality of PVs encodes the E5 protein. High-risk HPV types, including HPV18, encode 
one E5α protein. Low-risk HPV types such as HPV11 encode two E5 proteins: E5γ and E5δ 
(Figure 3) (DiMaio & Petti, 2013). High-risk and low-risk HPV E5 proteins are different. 
Nevertheless, their expression correlates with higher risk of cancer suggesting that E5 proteins 
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can enhance the transforming properties of E6 and E7 oncogenic proteins (Bravo & Alonso, 
2004). Also, the E5 protein interacts with different cellular factors, but their role in the HPV 
life cycle is poorly understood (DiMaio & Petti, 2013). 
The main function of the E6 protein is to restore the proliferation of differentiated cells (Oh et 
al., 2004). When a cell enters the unplanned S-phase, it is typically directed to apoptosis. The 
HPV E6 oncogenic protein binds to a cellular E6-associated protein (E6-AP), and the complex 
E6/E6-AP binds to major tumor suppressor protein 53 (p53), which results in a rapid ubiquitin-
dependent degradation of p53 (Yim & Park, 2005). E6 shows the ability to block other apoptotic 
pathways as well, so abnormally active mitotic cells can support viral replication (Howie et al., 
2009).  
The E7 protein acts in cooperation with the E6 protein, but targets retinoblastoma (pRb) tumor 
suppressor protein (Moody & Laimins, 2010). pRb protein in complex with the E2F 
transcription factor regulates the entry into the S-phase of the cell cycle, when a cell genome 
replicates. When the E7 protein binds to the pRb protein, pRb is directed to degradation and the 
transcription factor E2F is released from the inhibitory complex (Yim & Park, 2005). Next, the 
host cell division and DNA replication are activated enabling simultaneous replication of the 
HPV genome. The oncogenic potential of E5, E6, and E7 of high-risk HPVs is higher due to 
their higher affinity for cellular tumor suppressor proteins (Moody & Laimins, 2010). 
1.4.2.2 Late region proteins 
The icosahedral, non-enveloped HPV virions consist of two types of proteins: major capsid 
protein L1 and minor capsid protein L2, whereas only the L1 protein is present on the HPV 
surface (Buck et al., 2013). The synthesis of capsid proteins occurs at the final stages of the 
virus life cycle followed with packaging and release of virions into the environment. It is 
assumed that L1 participates in primary interaction of HPV with the host cell and assists viral 
genome trafficking in the nucleus (Letian & Tianyu, 2010). L2 is believed to play an important 
role in the encapsidation of the circular and nucleosome-bound viral genome during assembly 
of the virions in the nucleus of the host cell (Wang & Roden, 2013). Recombinant L1 protein 
self-assembled virus-like particles (VPLs) is the main direction of the development of vaccines 
against HPV infections (Wang & Roden, 2014). In contrast to L1, the L2 protein cannot 
assemble into VPLs, but L2 co-assembled with L1 enhances stability of the produced VLPs 
(Wang & Roden, 2013).  
16 
 
1.5 E1 protein structure 
The E1 protein is encoded by the largest and one of the most conserved ORFs in the PV genome, 
which is located near the URR region after the E6 and E7 ORFs (Figure 3) (Bergvall et al., 
2013). A lot of understanding of the E1 protein structure and functions came from a similar, 
well-studied large T-antigen (LT) protein that belongs to Simian virus 40 (SV40) from the 
family Polyomaviridae (Clertant & Seif, 1984). Polyomaviridae and Papillomaviridae viruses 
use host cell DNA replication machinery in a similar manner for replication of their own 
genomes.  
The E1 protein is about 600-660 bp in length (Bergvall et al., 2013). It can be divided into three 
functional domains. The N-terminal part is the least conserved domain of the E1 protein (Amin 
et al., 2000). The central DBD binds to the specific sequence of the ori (Titolo et al., 2003). The 
C-terminal region possessing 3'-5' helicase activity has many functions in the active enzymatic 
form, and is responsible for unwinding short DNA duplexes (Sedman & Stenlund, 1998). A 
schematic representation of domains is shown in Figure 4. 
The N-terminal domain is about 200 amino acids. There are different motifs that are 
changeable in their sequence, but present practically in all PV types (Bergvall et al., 2013). 
These are bipartite nuclear localization signal (NLS), a Crm1-dependent nuclear export signal 
(NES), a cyclin-binding motif that interacts with cyclin A/E in complex with cyclin-dependent 
kinase 2 (Cdk2), and phosphorylation sites for Cdk2 and other kinases (Bergvall et al., 2013). 
All of them are essential for correct replication in vivo, but unnecessary for replication in vitro 
(Amin et al., 2000). 
The origin-binding domain (OBD) or DBD is needed to recognize specific sequences in the 
ori of viral DNA (Thorner et al., 1993). PVs have six E1-binding sites (E1BS1 to E1BS6) of 
consensus sequence 5′-ATTGTT-3′ in the E1 binding region (Titolo et al., 2003). Some of these 
sites can be degenerated or suffer from lower affinity for E1 (Chen & Stenlund, 2001). The 
DBD region in general has low affinity for E1BSs, and the E1-E2 complex is required for 
effective binding of E1 to the ori (Thorner et al., 1993). Even dimerization of E1 proteins 
increases the affinity of the DBD for its consensus sequence by around 10 times (Titolo et al., 
2003). 
The enzymatic C-terminal helicase domain (HD) is required for correct unwinding of DNA 
during the replication. Also, it interacts with the TA domain of the E2 protein when the pre-
helical complex is forming at the ori (Yang et al., 1993). The HD can be also subdivided into 
three different functional regions (Figure 4). These are the minimal oligomerization domain, 
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which participates in the formation of the correct hexameric complex, the AAA+ superfamily 
domain with ATPase activity, and the C-terminal brace (Sedman & Stenlund, 1998). The role 
of the C-terminal brace is not fully understood, but it may be important for the stabilization of 
the oligomeric state of E1 when the enzymatic E1 helicase complex faces conformational 
changes during the binding and hydrolysis of ATP (Whelan et al., 2012). 
The helicase activity of HPV is absolutely needed for correct replication of the HPV genome. 
Therefore, it is a good target for antiviral drugs. Only a few drugs inhibiting ATPase activity of 
the hexameric E1 complex or repressing the interactions between E1 and E2 have been found. 
This inhibition results in lower levels of HPV replication yielding a lower amount of HPV 
genomes per cell (Archambault & Melendy, 2015). 
 
 
Figure 4. Schematic representation of E1 protein structure. E1 protein can be subdivided into 
three regions. The N-terminal domain is essential for viral DNA replication and contains 
regulatory sequences. The DBD is located in the center. It has low binding specificity to viral 
genome and requires the E2 protein to initiate replication. The C-terminal domain has three 
parts: oligomerization domain (O), which has an important role in forming active helicase 
complex, ATPase domain, and C-terminal brace responsible for stabilization (Bergvall et al., 
2013). 
1.6 Role of E1 in the life cycle of HPVs 
The main function of the E1 protein during the HPV life cycle is to initiate the replication of 
the HPV genome, which is further accomplished mainly with the help of the host cell replication 
machinery. E1 and E2 are the only viral proteins required for HPV replication (Yang et al., 
1993). Also, the E1 protein interacts with several cellular factors needed for replication of the 
HPV genome, like DNA polymerase α-primase (Pol α-prim) complex, replication protein A 
(RPA) or topoisomerase I (Topo I) (Melendy et al., 1995). Moreover, the E1 protein can 
produce double-strand DNA breaks (DSBs) in the host cell genome, which results in the 
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activation of DNA damage response (DDR) pathways and induces recombination-dependent 
replication of HPV DNA (Sakakibara et al., 2011). 
1.6.1 E1 and replication of the HPV genome 
Since E1 itself can poorly bind to DNA, it cooperates with the E2 protein that binds with high 
affinity to four E2-specific palindromic motifs located at the ori (Ustav et al., 1993). The E2 
protein assists loading of E1 specifically at the ori and prevents nonspecific interactions 
between the DBD of E1 and cellular DNA. Their interaction occurs via the E2 N-terminal TA 
domain and the E1 C-terminal region (Berg & Stenlund, 1997).  
ATP is allosteric effector of E1-E2 complex dissociation. ATP promotes the oligomerization 
of the E1 hexameric complex. ATP and the E2 TA domain compete with each other for binding 
to the E1 C-terminal HD, but they interact with different motifs of the E1 helicase region. When 
ATP is present near the ori, it can bind to the E1-E2 complex and promote its transition to the 
E1 double-trimer (DT) complex (Bergvall et al., 2013). The E1 DT complex transforms into 
the double-hexamer (DH) complex, which forms a ring-like structure and is known as the active 
enzymatic form of the E1 protein that can perform bi-directional melting of the viral genome at 
the ori. Each E1 active enzymatic hexamer complex encircles one DNA strand (Sedman & 
Stenlund, 1998). A schematic representation of this process is present in Figure 5. 
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Figure 5. Assembly of the active enzymatic E1 complex. Firstly, E1 dimer binds to E1BS at 
the ori with the help of E2 proteins. ATP sets free E2 protein molecules, and the E1 double-
trimer (DT) complex is formed. Thereafter, a subsequent helicase double-hexamer (DH) 
complex forms, and replication can be started with the help of cellular factors (Bergvall et al., 
2013). 
1.6.2 Interactions between E1 and host cellular factors  
E1 plays an important role not only in replication of the HPV genome, but also in a wide 
spectrum of other viral life cycle processes. E1 is responsible for interactions with a huge 
variety of cellular proteins, some of them are p80/Uaf1, Cyclin A/E-Cdk2, Ini1/hSNF5, Hsp40, 
Hsp70, Histone H1, E1-BP/TRIP13, and Importins (Bergvall et al., 2013). 
E1 interacts using the DBD and the HD with Topo I, which is an ATP-independent protein that 
decreases torsional stress in DNA and modifies the topology of supercoiled DNA, which results 
in increased binding of E1 to the ori and faster assembly into the active enzymatic form (Clower 
et al., 2006). The next important protein is replication protein A (RPA), which also interacts 
with the E1 DBD. During the replication, E1-bound RPA molecules dissociate from E1 and 
bind to naked single-stranded DNA (ssDNA) of the lagging strand (Loo & Melendy, 2004). 
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Also, E1 interacts with the DNA polymerase α-primase (Pol α-prim) complex (Park et al., 
1994). The Pol α-prim complex makes RNA-DNA primers, which are needed for DNA 
Polymerase δ to synthesize a total DNA sequence of the lagging and leading strands (Prindle 
& Loeb, 2012). Interestingly, Pol α-prim binds to E1 only after the dissociation of the E1-E2 
complex (Amin et al., 2000). To prevent re-association of Pol α-prim in vitro, HPVs need 
replication factor C (RFC) in cooperation with RPA molecules. RFC also loads the proliferating 
cell nuclear antigen (PCNA) and DNA polymerase δ for the synthesis of remain DNA (Melendy 
et al., 1995). Interactions of the E1 protein or other viral proteins with these cellular factors 
have not been reported in vivo (Bergvall et al., 2013). 
1.6.3 E1 toxicity for the host cell and regulation of E1 
E1 is a very toxic protein for host cell DNA. Therefore, the levels of E1 are regulated tightly 
by synthesizing a very low amount of E1 or by its degradation (Sakakibara et al., 2011). Studies 
with bovine papillomavirus type 1 (BPV1) E1 showed that E1 forms the complex with cyclin 
E/Cdk2 that stabilizes E1 before HPV genomic replication (Cueille et al., 1998). However, E1 
becomes destabilized again during the replication cycle and is degraded with the help of the 
ubiquitin-proteasome pathway, which needs poly-ubiquitination of the E1 protein by the 
anaphase-promoting complex/cyclosome (Mechali et al., 2004). 
E1 is regulated by different post-translational modifications. For instance, subcellular 
localization of E1 is regulated by phosphorylation (Lentz et al., 1993). E1 is also subjected to 
sumoylation or covalent attachment of a small ubiquitin-like modifier (SUMO) that is 
suggested to affect the enzymatic activity of E1 (Fradet-Turcotte et al., 2009). During the 
vegetative replication, HPV activates caspases-3, -7, and -9 that promote specific cleavage of 
E1 (Bergvall et al., 2013). However, it is currently unknown how E1 proteolytic cleavage helps 
with the genome amplification during the productive phase (Richard & Tulasne, 2012).  
1.6.4 E1-induced DNA damage response 
Nuclear accumulation of the E1 active enzymatic form arrests the cell cycle in the S-phase and 
blocks the proliferation of the host cell (Fradet-Turcotte et al., 2011). The E1 NLS in 
combination with the NES forms a pathway that delicately controls the levels of replication of 
the HPV genome during the S-phase in the host cell nucleus (Fradet-Turcotte et al., 2010). 
E1 active helicase always tries to initiate host DNA replication thereby inducing cellular DNA 
DSBs that activate the DDR pathways in the host cell. E2 in complex with E1 attenuates the 
ability of inducing DSBs, but does not fully prevent it, so the DDR takes place during HPV 
genome replication (Fradet-Turcotte et al., 2011). The main DDR pathways are ataxia-
21 
 
telangiectasia mutated (ATM) kinase signaling pathway and ATR (ATM and Rad3-related) 
pathway (Reinson et al., 2013). These pathways can activate homologous recombination, and 
virus can use it to replicate its own genome during the vegetative amplification stage (Moody 
& Laimins, 2009).  
E1-dependent DBSs can induce host genomic instability and promote the integration of the 
HPV genome is the host cell genome (Moody & Laimins, 2010). Integration of high-risk HPV 
genomes is one of the factors that can lead to cancer (Pett & Coleman, 2007). 
1.7 Difficulties to study the HPV life cycle 
The HPV infection cycle is closely connected with programmed differentiation of keratinocyte 
stem cells. Because of this fact, most of eukaryotic cell lines do not support HPV replication 
and are unsuitable for studying the HPV life cycle. One method to study the HPV life cycle is 
organotypic raft cultures. They are either derived from biopsies (primary human keratinocytes 
or cervical carcinoma dysplasia) or created by transfection of keratinocytes with HPV DNA 
(Anacker & Moody, 2012). High cost and low efficiency are the raft culture disadvantages since 
low-risk HPVs cannot immortalize keratinocytes and their transcripts are poorly detected. 
There are some HPV-positive cell lines available. For instance, the HPV31b+ CIN 612 cell line 
is derived from human cervical intraepithelial neoplasia (CIN), HPV16+ W12 cell line is 
established from epithelial cells of low-grade cervical lesion, and HPV16+ KG cell line is 
designed from a vulvar intraepithelial neoplasm (De Geest et al., 1993; Doorbar et al., 1990; 
Grassmann et al., 1996). All these cell lines are suitable for studying the life cycle of their 
specific HPV types only. 
The molecular virology research group (Institute of Technology, University of Tartu) has 
developed a cellular system for studying different HPV types (Geimanen et al., 2011). It is 
based on the U2OS cell line derived from human osteosarcoma. The greatest benefit of this 
system is that it can support replication of not only high-risk HPVs like HPV16 and HPV18, 
but also low-risk HPVs (HPV6b and HPV11) and cutaneous types (HPV5 and HPV8). 
Although the U2OS cell line does not allow studying the entire HPV life cycle from entry to 
the cell to encapsidation of viral genomes, it perfectly supports the study of all three HPV 
replication phases. The U2OS cell line is used also in the present study.  
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2. EXPERIMENTAL PART 
2.1 Aims of the study 
The general purpose of this study is to create new E1-HA HPV11 and E1-HA HPV18 constructs 
by cloning the HA-tag encoding sequence in E1 ORF of the viral genomes with the subsequent 
goal to use the constructs in further studies. Step-by-step aims of the work are: 
-Synthesis of viral DNA fragments containing HA-tag within them; 
-Cloning of the synthesized DNA fragments into the HPV parental genomes; 
-Comparison of the replication status of wtHPVs and the created E1-HA HPV constructs in the 
U2OS cell line. 
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2.2 Materials and methods 
2.2.1 Plasmids used in the present study 
 pJET1.2/blunt Vector (2974 bp). This is a vector designed for cloning blunt-ended 
polymerase chain reaction (PCR) products (CloneJET PCR Cloning Kit, Thermo Fisher 
Scientific). It contains the β-lactamase bla gene, which gives resistance to ampicillin 
(ApR), specific primer binding sites, and a multiple cloning site (MCS).  
 pMC.BESPX (4084 bp). This vector contains the following elements necessary and 
sufficient for production of minicircle plasmids: attB and attP sites, where 
bacteriophage ФC31 integrase can bind, 32 restriction sites of SceI endonuclease, MCS, 
kanamycin resistance gene (KanR), and the origin of bacterial replication (ColE1 ori) 
(Kay et al., 2010).  
 HPV11-pMC.BESPX (12015 bp). This plasmid was constructed to produce HPV11 
minicircle plasmids by cloning wtHPV11 genomic DNA into the BamHI site of the 
pMC.BESPX vector (Orav et al., 2015). 
 HPV11 minicircle DNA plasmid (7967 bp). Covalently closed, supercoiled, circular 
plasmid produced from HPV11-pMC.BESPX. It differs from wtHPV11 DNA by only 
36 bp in length attR sequence in its URR that was formed during the process of 
recombination by integrase ФC31. 
 HPV18-pMC.BESPX (11974 bp). This plasmid contains wtHPV18 genomic DNA 
cloned into the pMC.BESPX vector between attP and attB sites (Orav et al., 2013). 
 HPV18 minicircle DNA plasmid (7893 bp). This plasmid was produced analogously 
to the previously described HPV11 minicircle DNA plasmid. 
2.2.2 Generation of E1-HA HPV11/HPV18-pMC.BESPX constructs 
2.2.2.1 PCR 
To synthesize and amplify HPV fragments containing the HA-tag encoding sequence, I used 
PCR and primers listed in Table 1. The synthesis was performed using Pfu DNA polymerase 
(Thermo Fisher Scientific), HPV11/HPV18-pMC.BESPX DNA constructs as templates for 
amplification and PCR Mastercycler (Eppendorf Scientific). The PCR components are listed in 
Table 2. The first step of the PCR program was initial denaturation of template DNA for 3 min 
(95 ˚C). The second part of the reaction comprised 20 cycles of the synthesis: 30 s of 
denaturation (95 ˚C), 30 s of annealing of the primers (57 ˚C), and 4 min of extension (72 ˚C). 
The last step was the final extension for 5 min (72 ˚C) and cooling to 10 ˚C. 
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Table 1. Primers used during the work. The underlined sequence encodes HA-tag. The primers 
contain the following restriction sites depicted as indicated in the parentheses: NheI (green), 
BshTI (red), SwaI (yellow), Bpu1102I (grey), and AatII (pink). Sequences complementary to 
viral genomes are shown in italic. 
# Primer: Sequence: 
1 HPV11 E1-HA BshTI FW ACCGGTTTCGGTTACCCACACCC 
2 HPV11 E1-HA NheI REV GCTAGCGTAATCTGGAACATCGTATGGGTATG 
AATCGTCCGCCATC 
3 HPV11 E1-HA NheI FW GCTAGCGGTACAGAAAATGAGGG 
4 HPV11 E1-HA SwaI RV ATTTAAATTGACTGTCAGCCAAAC 
5 HPV18E1-HA Bpu1102I FW     GCTCAGCAGACGACCTTCGAGC 
6 HPV18E1-HA NheI RV GCTAGCGTAATCTGGAACATCGTATGGGTATT 
CTGGATCAGCCATTG 
7 HPV18E1-HA NheI FW GCTAGCGGTACAGACGGGGAGG 
8 HPV18E1-HA AatII RV GACGTCTGGCCGTAGGTCTTTGC 
9 Sequencing HPV18 E1 seq CCTGTTGCGTTACAAATGTGG 
 
Table 2. Reagents for the PCR. 
Reaction components: Volume (µl): 
10x Pfu Buffer with MoSO4 5 
dNTP mix, 2 mM each 5 
Forward primer 10 µM 5 
Reverse primer 10 µM 5 
Template DNA, 18 ng/µl 2 
Pfu DNA polymerase 1 
MQ water 27 
Total volume 50 
 
2.2.2.2 Gel electrophoresis 
I analyzed the obtained PCR products using the method of gel electrophoresis. After the PCR, 
I loaded the mixes on 2% agarose gel containing 0.3 µg/ml of ethidium bromide in the presence 
of the following DNA ladders: 0.6 µg of O’GeneRuler 1kb and 0.8 µg of pUC19 DNA Mspl 
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(HpaII) (both Thermo Fisher Scientific). The gel ran for 45 min in 1xTAE (40 mM Tris-acetate, 
1 mM EDTA) buffer under 100 V. After separation of fragments on the gel, I cut out the 
required fragments with scalpel under UV (260 nm) and put them into clean 1.5 ml tubes. 
2.2.2.3 DNA extraction from the gel 
Each fragment was carefully extracted from the gel using QIAEX II Gel Extraction Kit 
(Qiagen) and according to manufacturer`s instructions. Gel pieces with DNA were dissolved in 
a QIAEX II solution at 50 ˚C and loaded to the columns. After centrifugation with Biofuge pico 
(Heraeus) at room temperature (RT) and 5000 rpm, DNA remained bound to silica resin and 
the flow-through was removed. The column-bound DNA was washed with QX1 and PE buffers 
and then eluted in 10 µl of pure water. The concentrations were measured using a Nanodrop-
1000 spectrophotometer (Thermo Fisher Scientific) at 260 nm wavelength. 
2.2.2.4 Cloning of the PCR products into the vector 
The purified PCR products were cloned into the pJET1.2/blunt cloning vector. The ligation 
reaction components are listed in Table 3. The reactions were performed at RT for 1 h.  
Table 3. Ligation reaction of the purified PCR products and cloning vector. 
Reaction components: Volume (µl): 
10x reaction Buffer 1 
pJET1.2/blunt cloning vector (50 ng/µl) 0.3 
T4 DNA Ligase 1 
Purified PCR product 7.7 
Total volume 10 
 
2.2.2.5 Transformation in DH5α 
For the transformation, I used competent cells of nonpathogenic Escherichia coli strain DH5α, 
which were stored at −70 ˚C. Prior the transformation, competent cells were thawed on ice for 
20 min. Each of four separate 10 µl ligation mixes were added to 200 µl of competent cells and 
incubated on ice for 30 min. After that, bacteria were incubated at 37 ˚C for 3 min and then 
transferred on ice for 1 min. Then I added 850 µl of LB broth (10 g/l tryptone, 5 g/l yeast extract, 
10 g/l NaCl) to each tube and incubated them at 37 ˚C for 45 min. The tubes were centrifuged 
for 5 min at 5000 rpm and RT, and then supernatant was removed. Bacteria were resuspended 
in 100 µl of LB broth and plated using the spread plate technique on LB agar supplemented 
with 50 µg/ml of ampicillin. The plates were incubated at 37 ˚C for 18 h. After that, several 
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colonies were transferred from plates to 3 ml of LB broth containing 200 µg/ml of ampicillin 
and incubated at 37 ˚C, 220 rpm for 18 h. 
2.2.2.6 Plasmid DNA extraction 
Plasmid DNA was extracted from bacteria using Plasmid Extraction Mini Kit (Flavoprep) 
according to manufacturer’s protocol. All procedures were performed at RT. First, I centrifuged 
bacteria at 5000 rpm for 5 min. After removal of supernatant, the pellet was resuspended in 
FAPD1 buffer containing RNase A. Bacteria were lysed in FAPD2 buffer, and then reactions 
were neutralized with FAPD3 buffer. After centrifugation at 13 000 rpm for 5 min, supernatant 
containing DNA was transferred to the FAPD column and centrifuged. The column-bound 
DNA was washed with W1 and Wash buffers, and then eluted with 40 µl of nuclease-free water.  
2.2.2.7 Precipitation of DNA 
If the concentrations of the obtained DNA were low, I precipitated DNA using 1/10 V (volume 
of the DNA sample) of 5 M NaCl and 2 V of 96% ethanol per 1 V of sample. The samples were 
mixed by vortexing and centrifuged at 4 ˚C and 15000 rpm for 20 min using MicroCL 21R 
Microcentrifuge (Thermo Fisher Scientific). After removal of supernatant, the pellets were 
washed with cold (−20 ˚ C) 75% ethanol and centrifuged for 7 min at 4 ˚ C and 15000 rpm. Then, 
the pellets were dried and resuspended in 10 µl of nuclease-free water.  
2.2.2.8 Control of the cloned PCR products with restriction 
The restriction analysis was used to control the presence and size of our PCR products in the 
pJET1.2/blunt cloning vector. I used restriction enzymes specific for the sites encoded by 5’-
end of each primer and defined in primers’ name (Table 1). All restriction enzymes were 
purchased from Thermo Fisher Scientific. I took 0.5 µl of each restriction enzyme (10 U/µl), 
500 ng of each DNA sample, and 2 µl of 10x FastDigest green Buffer (total volume of a reaction 
was 20 µl). The restriction reactions were done at 37 ˚C for 1 h. The restricted DNA was 
visualized under UV (260 nm) using the gel electrophoresis method as described in section 
2.2.2.2.  
2.2.2.9 DNA sequencing  
The PCR products were verified by DNA sequencing using primers specific for the 
pJET1.2/blunt cloning vector: pJET1.2 Forward and pJET1.2 Reverse Sequencing Primers 
(CloneJET PCR Cloning Kit, Thermo Fisher Scientific). For sequencing of the HPV18 2625 bp 
PCR product synthesized with primers #7 and #8, I also used primer #9 (Table 1), which is 
complementary to 1765-1785 bp of the HPV18 genome (hereafter, numbering is given 
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according to the HPV11 and HPV18 reference sequences listed in the PaVE database [1]). DNA 
sequencing was performed in Estonian Biocenter Core Laboratory, Tartu, Estonia. The correct 
DNA clones verified by sequencing were chosen for further cloning.  
2.2.2.10 Ligation of the obtained PCR products and parental HPV genomes  
In order to clone the appropriate DNA fragments from the pJET1.2/blunt vector into HPV-
pMC.BESPX parental plasmids, first, I digested all plasmids with the respective restriction 
enzymes. The restriction was performed as described in section 2.2.2.8. I used 5 µg of parental 
plasmids, 8 µg of plasmids containing PCR products obtained using primers #1/2, #3/4, and 
#7/8, and 30 µg of plasmid containing a 137 bp PCR product synthesized with primers #5/6. 
The fragments were separated using gel electrophoresis, and then the fragments required for 
subsequent ligation were purified from the agarose gel as described in section 2.2.2.3. The 
ligation reactions contained 100 ng of parental plasmid, 300 ng of each fragment, 1 µl of 10x 
reaction Buffer and 1 µl of T4 DNA Ligase. The ligation mixes were incubated at 16 ˚C 
overnight and then transformed to competent DH5α. Bacteria were plated on LB-agar 
containing 25 µg/ml of kanamycin. The plasmid DNA was isolated and verified by the 
restriction analysis using the relevant restriction enzymes and also by DNA sequencing. The 
resulted correct constructs were defined as E1-HA HPV11-pMC.BESPX and E1-HA HPV18-
pMC.BESPX. 
2.2.2.11 Production of minicircles 
Replication of the HPV genome containing bacterial DNA is low-efficient and disparate with 
replication of wtHPV. All viral genomes used in the replication assay of this study were 
produced using the minicircle DNA technology (Kay et al., 2010).  
For producing minicircles, I used Escherichia coli strain ZYCY10P3S2T. The genome of this 
strain encodes specific recombinase ФC31 and SceI endonuclease under the inducible L-
arabinose PBAD promotor (ara-BAD operon). I transformed E1-HA HPV11-pMC.BESPX and 
E1-HA HPV18-pMC.BESPX plasmids into ZYCY10P3S2T strain and plate bacteria on LB-
agar plates containing 25 µg/ml of kanamycin. Bacteria were incubated at 37 ˚C for 18 h. 
Bacteria from one colony were transferred into 3 ml LB-broth supplemented with 50 µg/ml of 
kanamycin, incubated at 37 ˚C, 220 rpm for 8 h, and then transferred into 100 ml of Difco 
Terrific broth containing 25 µg/ml of kanamycin. Bacteria were grown at 37 ˚C, 220 rpm for 
16 h. Then, I added 100 ml of an inducing solution consisting of LB containing 0.4M NaOH 
and 0.04% L-arabinose and continued incubation at 32 ˚C, 220 rpm for 8 h. Then, I centrifuged 
bacteria at RT and 5000 rpm for 10 min and used Plasmid Extraction Mini Kit (Flavoprep) to 
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extract minicircles in a similar way as described in section 2.2.2.6. The resulted E1-HA HPV11 
and E1-HA HPV18 minicircles were used in further experiments.  
2.2.3 Electroporation of the U2OS cell line and isolation of total DNA 
2.2.3.1 U2OS cell line and used medium 
In this study, I used human osteosarcoma cell line U2OS (Geimanen et al., 2011). Cells were 
grown in 10 cm plates (Corning Inc.) in the normal growth medium (NGM) consisting of 
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% fetal bovine serum 
(FBS), penicillin (100 IU/ml), and streptomycin (100 ng/ml) (Sigma-Aldrich). Cells were 
incubated at 37 ˚C and 5% of CO2. 
2.2.3.2 Transfection of U2OS cells by electroporation 
Confluent U2OS cells were split 1:2 approximately 24 h before transfection. On the next day, 
the medium was removed and the cells were washed with a PBS solution (137 mM NaCl, 2.7 
mM KCl, 4.3 mM Na2HPO4, and 1.47 mM KH2PO4). Then, the cells were detached using 0.8 
ml of a 0.25% Trypsin-EDTA solution and transferred into 6 ml of a fresh NGM. The cells 
were counted using a Countess Automated Cell Counter (Thermo Fisher Scientific). I used 
approximately 1.2 × 106 cells per each electroporation. The required amount of the cells was 
centrifuged at 20 ˚ C and 1000 rpm for 5 min using Eppendorf Centrifuge 5810R (Thermo Fisher 
Scientific) and then resuspended in 250 µl of the NGM. The cells were mixed with HPV 
genomes and 50 µg of salmon sperm DNA. The following amounts of the viral genomes were 
used for electroporation of 1.2 × 106 cells: 600 ng of HPV11 and E1-HA HPV11 minicircle 
DNA and 1600 ng of HPV18 and E1-HA HPV18 minicircle DNA. Suspension of the cells with 
DNA was transferred in a cuvette for electroporation with a gap size of 4 mm. Electroporation 
was performed using a Gene Pulser XCell machine (Bio-Rad Instruments) at 220 V voltage and 
975 µF capacity. After electroporation, I transferred the cells in 4 ml of a fresh NGM and 
centrifuged them at 20 ˚C, 1000 rpm for 5 min. Then, I resuspended the cells in 6 ml of the 
NGM and equally divided them between three wells of 6-well plates (Corning Inc.) using 2 ml 
of cell suspension per one well.  
2.2.3.3 Extraction of total DNA from U2OS cells 
Prior lysis, the cells were washed with 2 ml of PBS and then lysed in 500 µl of Proteinase K 
buffer (20 mM Tris pH 8.0, 100 mM NaCl, 0.1 g/l mM EDTA, 0.2% SDS). Then, I mixed the 
lysates with Proteinase K (final concentration 200 µg/ml) using insulin syringe and incubated 
at 56 ˚C overnight. Hydrolyzed proteins were removed using the phenol-chloroform extraction 
29 
 
method. I added 500 µl of phenol-chloroform (1:1) mix to each lysate and vortexed them for 
15 s. After centrifugation at RT, 13000 rpm for 2 min, I transferred the upper aqueous phase 
containing DNA to a new 1.5 ml tube. Then, I added 2 volumes of 96% ethanol to each tube to 
precipitate the DNA. After vigorous mixing with subsequent 30 min of incubation at −20 ˚C 
and centrifugation at 4 ˚C, 15000 rpm for 20 min, supernatants were removed and dried pellets 
were resuspended in 100 µl of TE (10 mM Tris, 1 mM EDTA pH 8.0) containing 40 ng of 
RNase A by vortexing. The mixtures were incubated at 37 ˚C for 1 h. After that, I precipitated 
DNA as described in section 2.2.2.7 and dissolved the pellets in 40 µl of TE.  
2.2.4 Southern Blot 
2.2.4.1 Restriction of extracted total DNA 
The obtained total DNA samples containing genomic, mitochondrial, and viral DNA were 
analyzed using the Southern Blot method. For the restriction, I took 2 µg of samples containing 
HPV11 and E1-HA HPV11 minicircle DNA and 3 µg of samples containing HPV18 and E1-
HA HPV18 minicircle DNA. I used 2 µl of each restriction enzyme and 4 µl of 10x FastDigest 
green Buffer per one reaction in 40 µl of the total volume. The reactions were performed at 37 
˚C overnight.  
2.2.4.2 Transfer of DNA from the gel to a nylon membrane 
The DNA fragments obtained after the restriction were separated on a 0.8% agarose gel 
containing 0.3 µg/ml of ethidium bromide. The gel was run in 1xTAE buffer for 17 h under 25 
V in the presence of 8 µg of O’GeneRuler 1kb DNA ladder. In order to denature dsDNA, I 
incubated the gel in alkali Solution A (0.5M NaOH, 1.5M NaCl) at RT and 100 rpm for 40 min 
and then washed with distilled water. Secondly, I incubated the gel in Solution B (1M Tris pH 
8.0, 1.5M NaCl) at RT and 100 rpm for 30 min. Then, DNA from the gel was transferred to a 
nylon membrane (Millipore) using the upward capillary transfer method in 10x saline-sodium 
citrate buffer 10x SSC (1.5M NaCl, 150 mM Na3C6H5O7) for 18 h.  
2.2.4.3 Hybridization 
After the transfer, DNA was cross-linked to the membrane using UV (Stratalinker). After that, 
to prevent nonspecific binding, I incubated the membranes in 30 ml of a prehybridization 
solution (16 ml MQ water, 9 ml 20x SSC, 3 ml 50x Denhadrt’s solution, 1.5 ml 10% SDS, 0.6 
ml of denaturated at 100 ˚C salmon sperm DNA (10 µg/µl)) at 65 ˚C for 45 min in rolling tubes. 
For synthesis of hybridization probes, HPV11 and HPV18 minicircle DNAs were initially 
linearized using HindIII and BglI restriction enzymes, respectively, and then purified from 
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agarose gel as described in section 2.2.2.3. Hybridization probes were synthesized using 100 
ng of linearized and purified HPV11 and HPV18 minicircle DNAs as templates and DecaLabel 
TM DNA Labeling Kit (Thermo Fisher Scientific).  
First, 10 µl of decanucleotide primers were added to the DNA template in a total volume of 40 
µl. The samples were incubated at 100 ˚C for 10 min and then placed on ice. Next, 3 µl of mix 
C containing all dNTPs except for dCTP, 4 µl of α-32P-dCTP isotope (Hartman Analytics), and 
1 µl of Klenow Fragment lacking 5’-3’ exonuclease activity were added, and the samples were 
incubated at 37 ˚C for 15 min. Then I added 4 µl of dNTP. The reactions were incubated at 37 
˚C for additional 15 min and then stopped by adding 1 µl of 0.5M EDTA and denaturation at 
100 ˚ C for 10 min. After that, I added HPV11 and HPV18 hybridization probes to the respective 
membranes incubated in the prehybridization solution. The membranes were incubated at 65 
˚C overnight. Next day, I washed the membranes with washing solutions pre-heated at 65 ˚C. 
First, I washed them twice with solution I (10xSSC, 0.1% SDS) for 5 min, then once with 
solution II (5xSSC, 0.1% SDS) for 15 min and twice with solution III (0.5xSSC, 0.1% SDS) 
for 10 min. All washings were performed at 65 ˚C. 
2.2.4.4 Detection of viral DNA signals 
After the hybridization, the membranes were exposed to an X-ray film in cassettes at −70 ˚C 
for about 5 and 9 h for HPV11 and HPV18, respectively. The X-ray film was developed and 
fixed using AGFA Developer and Rapid Fixer solutions. 
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2.3 Results 
2.3.1 Synthesis of fragments of HPV11/HPV18 DNA with the HA-tag 
encoding sequence 
In order to generate new HPV constructs containing the sequence encoding Human influenza 
hemagglutinin tag (HA-tag, 5’-TACCCATACGATGTTCCAGATTACGCT-3’), I cloned the 
sequence into E1 ORFs of the HPV genomes. First of all, I used the PCR and primers, listed in 
Table 1 to synthesize the HA-tag encoding sequence after the 15th nucleotide of E1 ORF 
(numbering is given from the 1st ATG codon of E1) in the context of the HPV11 and HPV18 
genomes. 
Primers #2 and #6 contain the HA-tag encoding sequence with the NheI restriction site 
(G↓CTAGC) and also 16 and 17 nucleotides complementary to HPV11 and HPV18 genomic 
DNAs in positions 823-838 and 912-928, respectively. Primers #3 and #7 are complementary 
to HPV11 nucleotides 839-855 and HPV18 nucleotides 929-944 and additionally contain the 
NheI restriction site absent in original HPV11- and HPV18-pMC.BESPX constructs. Primers 
#1 and #4 are complementary to HPV11 genomic DNA in positions 7883-7905 and 1872-1895, 
respectively, and have restriction sites BshTI (5’-A↓CCGGT-3’) and SwaI (5’-ATTT↓AAAT-
3’) at their 5` ends. Primers #5 and #8 are complementary to the HPV18 genome in positions 
822-843 and 3525-3547, respectively, and contain Bpu1102I (5’-GC↓TNAGC-3') and AatII 
(5’-GACGT↓C-3’) restriction sites at their 5` ends. The obtained DNA amplicons were 
analyzed using agarose gel electrophoresis (Figure 6). 
The expected length of the PCR products obtained using primer pairs #1/2 and #3/4 for HPV11 
was 918 bp and 1063 bp, respectively. The expected size of the PCR products synthesized using 
primer pairs #5/6 and #7/8 for HPV18 was 137 bp and 2625 bp, respectively.  
Then, I excised and purified the PCR products from the agarose gel and measured the DNA 
concentrations. The obtained concentrations of the purified PCR products are listed in Table 4. 
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______________________________ 
Figure 6. Agarose gel electrophoresis analysis of the fragments of the HPV11 and HPV18 
genomes amplified by the PCR. I used DNA ladders O’GeneRuler 1kb (M1) and pUC19 DNA 
Mspl (HpaII) (M2). The obtained PCR products were: (1) 918 bp product of HPV11 primers 
#1/2, (2) 1063 bp product of HPV11 primers #3/4, (3) 137 bp product of HPV18 primers #5/6, 
and (4) 2625 bp product of HPV18 primers #5/6. The length of the DNA amplicons matches 
the expected size. 
Table 4. Concentrations of the obtained PCR products. 
PCR product: Concentration (ng/µl): 
918 bp fragment for HPV11 synthesized 
with primers #1/2 
34 
1063 bp fragment for HPV11 synthesized 
with primers #3/4 
53 
137 bp fragment for HPV18 synthesized 
with primers #5/6 
66 
2625 bp fragment for HPV18 synthesized 
with primers #7/8 
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2.3.2 Cloning the PCR products into the vector and controlling them with 
restriction and DNA sequencing  
Next, I cloned the obtained DNA fragments into the pJET1.2/blunt cloning vector. In order to 
verify the presence and size of the cloned DNA fragments, I isolated plasmid DNA from four 
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independent clones of each variant and performed the restriction analysis using restriction 
enzymes specific for sites encoded by 5`-ends of primers used for amplification of the fragments 
(Table 1). Data on the restriction analysis, restriction enzymes used and expected size of the 
DNA fragments are shown in Figure 7. 
 
Figure 7. Restriction analysis of the PCR products cloned into the pJET1.2/blunt cloning 
vector. A: clones of the HPV11 amplicons synthesized using primers #1/2 were cut using BshTI 
and NheI restriction enzymes. The expected length of the fragments was 918 and 2974 bp. B: 
clones of the HPV11 amplicons synthesized using primers #3/4 were cut using SwaI and NheI 
restriction enzymes. Cloning vector pJET1.2/blunt contains two SwaI-specific sites. The 
expected length of the fragments was 295, 298, 1063, and 2381 bp. C: clones of the HPV18 
amplicons synthesized using primers #5/6 were cut using Bpu1102I and NheI restriction 
enzymes. The expected length of the fragments was 137 and 2974 bp. D: clones of the HPV18 
amplicons synthesized using primers #7/8 were cut using AatII and NheI restriction enzymes. 
Cloning vector pJET1.2/blunt contains two AatII-specific sites. The expected length of the 
fragments was 376, 422, 2176, and 2625 bp. The arrows indicate the fragments with the size 
corresponding to that of the obtained PCR products; the asterisks indicate the clones possessed 
the expected restriction pattern and selected for sequencing. The numbers corresponding to the 
sizes of the cloned PCR products are underlined. DNA ladders O’GeneRuler 1kb (M1) and 
pUC19 DNA Mspl (HpaII) (M2) were used to detect the length of the obtained DNA fragments.  
The restriction pattern of clones 1(A), 2(A), 2(B), 3(B), 1(C), 2(C), 4(C), 1(D), and 4(D) 
corresponded to the expected one. Therefore, those clones were selected for DNA sequencing. 
DNA of clones 1(A), 2(B), 4(C), and 4(D) had no mutations. These clones were chosen for 
further assembling with the parental HPV11 and HPV18 genomes.  
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2.3.3 Generation of E1-HA HPV11/HPV18 minicircle constructs 
In order to clone the obtained correct DNA fragments into the parental HPV-pMC.BESPX 
genomes, I restricted HPV11-pMC.BESPX plasmid with BshTI and SwaI and HPV18-
pMC.BESPX with Bpu1102I and AatII. The length of the obtained fragments was 1940 bp and 
10075 bp for HPV11-pMC.BESPX and 2723 bp and 9251 bp for HPV18-pMC.BESPX. The 
data are shown in Figure 8.  
Then, the purified HPV11-pMC.BESPX 10075 bp fragment was ligated with the purified DNA 
fragments of clones 1(A) (918 bp) and 2(B) (1063 bp). On the other hand, the purified HPV18-
pMC.BESPX 9251 bp fragment was ligated with purified DNA fragments of clones 4(C) (137 
bp) and 4(D) (2625 bp). The ligation mixtures were transformed into DH5α bacteria, and 
plasmid DNA of 10 independent clones of supposed E1-HA HPV11-pMC.BESPX and 16 
clones of supposed E1-HA HPV18-pMC.BESPX was purified. After that, the obtained 
constructs were subjected to the restriction analysis. The data are shown in Figure 9.    
 
____________________________ 
Figure 8. Restriction of the parental HPV-pMC.BESPX genomes. I used O’GeneRuler 1kb as 
a marker. A: restriction of HPV11-pMC.BESPX with BshTI and SwaI restriction enzymes. B: 
restriction of HPV18-pMC.BESPX with Bpu1102I and AatII restriction enzymes. In both 
cases, the upper bands were excited from the agarose gel and purified. 
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Figure 9. Restriction analysis of several clones of the presumed E1-HA HPV11-pMC.BESPX 
and E1-HA HPV18-pMC.BESPX constructs. A: DNA of the supposed E1-HA HPV11-
pMC.BESPX clones was digested with BshTI/NheI or NheI/SwaI restriction enzymes. The 
expected size of the fragments was 918/11138 bp or 1063/10993 bp, respectively. B: DNA of 
the supposed E1-HA HPV18-pMC.BESPX clones was digested with NheI/AatII restriction 
enzymes. The expected size of the fragments was 2625 bp and 11876 bp. The clones 
demonstrated the expected restriction pattern are indicated by asterisks. M1: O’GeneRuler 1kb 
DNA ladder. 
Clones 8(A), 4(B), and 7(B) were selected for DNA sequencing. Clones 8(A) and 4(B) were 
correct. These clones named E1-HA HPV11-pMC.BESPX and E1-HA HPV18-pMC.BESPX, 
respectively, were used further for production of the respective minicircle DNAs referred later 
as E1-HA HPV11 and E1-HA HPV18. During the production of minicircles, a bacterial part of 
approximately 3 kbp was deleted from the E1-HA HPV11-pMC.BESPX and E1-HA HPV18-
pMC.BESPX plasmids and the size of the obtained minicircle DNAs was approximately 8 kbp.  
Obtained minicircles E1-HA HPV11 and E1-HA HPV18 were compared with the respective 
wtHPV minicircles using agarose gel electrophoresis. HPV DNA was either linearized or used 
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in its native form (Figure 10). The conformations and size of the obtained E1-HA HPV 
minicircles match those of the respective wtHPV genomes. 
 
 
______________________________________________________________________ 
Figure 10. Analysis of the conformations and size of the wtHPV and E1-HA HPV minicircles. 
I used DNA ladder O’GeneRuler 1kb (M1). The HPV11 minicircles were linearized using 
HindIII restriction enzyme (1) and (3); HPV18 minicircles were linearized using BglI restriction 
enzyme (5) and (7). Noncut HPV11, E1-HA HPV11, HPV18, and E1-HA HPV18 minicircle 
DNAs are shown in lanes 2, 4, 6, and 8, respectively. 
2.3.4 Comparison of the replication efficiencies of wtHPV11 with E1-HA 
HPV11 and wtHPV18 with E1-HA HPV18 minicircles 
The obtained E1-HA HPV11 and E1-HA HPV18 minicircle plasmids were used in the 
replication assay. I transfected U2OS cells with E1-HA HPV11, wtHPV11, E1-HA HPV18, 
and wtHPV18 minicircles and incubated cells for 3, 4, and 5 days. After the incubation period, 
I lysed the cells and extracted the total DNA from the samples. The DNA concentrations are 
listed in Table 5. 
Table 5. Concentrations (ng/µl) of the total DNA extracted from U2OS cells transfected with 
HPV11, E1-HA HPV11, HPV18, and E1-HA HPV18 minicircles. 
 3 days: 4 days: 5 days: 
wtHPV11 62 215 520 
E1-HA HPV11 81 233 575 
wtHPV18 223 139 590 
E1-HA HPV18 209 272 490 
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I restricted 2 µg of the total DNA of the samples containing HPV11 and E1-HA HPV11 DNA 
using restriction enzymes HindIII (10 U/µl) and DpnI (10 U/µl). HindIII linearizes HPV11 
DNA by cutting palindromic sequence 5'-A↓AGCTT-3'. DpnI cuts palindromic sequence 5’-
Gm6A↓TC-3’ in methylated by bacteria DNA, which was used initially for transfection. 
Treatment with DpnI allows to distinguish HPV DNA replicated in U2OS cells and input DNA 
used for transfection. For restriction of 3 µg of the total DNA samples containing HPV18 and 
E1-HA HPV18 minicircle DNA, I used restriction enzymes BglI (10 U/µl) and DpnI. BglI 
linearizes HPV18 DNA in palindromic sequence 5'-GCCNNNN↓NGGC-3'. The total DNA was 
separated on the agarose gel and visualized under UV (260 nm) (Figure 11A). 
Next, I transferred DNA from the gel to a nylon transfer membrane and hybridized it with 
radioactively labelled linearized HPV11 and HPV18 minicircle DNA. The data are shown in 
Figure 11B. The intensity of the radioactive signal at approximately 8 kb represents the level 
of viral DNA replicated in U2OS cells. The bands detected at approximately 4 kb on the right 
panel of Figure 11B are the fragments of DpnI-digested input DNA. The Southern blot analysis 
shows that the replication of E1-HA HPV11 and E1-HA HPV18 minicircles is similar to the 
respective wild-type genomes in U2OS cells indicating that presence of HA-tag does not impair 
the E1 biological activity. Therefore, E1-HA HPV11 and E1-HA HPV18 constructs can be used 
in further studies of E1 proteins and E1-dependent processes.  
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Figure 11. Comparison of the replication intensities of wtHPV11/E1-HA HPV11 and 
wtHPV18/E1-HA HPV18 minicircles in U2OS cells. A: total DNA containing wtHPV11, E1-
HA HPV11, wtHPV18, and E1-HA HPV18 was visualized under UV. B: radioactive signal 
showing replication of wtHPV11, E1-HA HPV11, wtHPV18, and E1-HA HPV18 minicircles 
after 3, 4, and 5 days after transfection of U2OS cells.  
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2.4 Discussion 
About 65-100% of sexually active people have HPV infection during their life. Most of them 
are asymptotic, but sometimes HPV infection may lead to different lesion progressions (Bucchi 
et al., 2016). About 98% of cervical carcinomas are associated with high-risk mucosal HPV 
infections (Winters et al., 2006). The study of the HPV infection cycle is essential for prevention 
and treatment of cancerous diseases. 
Since E1 protein is absolutely required for viral replication and inhibition of E1 activities can 
result in inhibiting viral infection, deeper knowledge of E1 functioning allows to work out novel 
strategies for manipulating E1 activities and developing new antiviral drugs targeting E1 
protein. For development of E1-specific antiviral drugs, it is needed to detect and purify 
biologically active E1 protein from cells, where HPV is replicating. Detection of endogenous 
E1 protein is very complicated because of its extremely low levels in host cells and lack of good 
and universal E1-specific antibodies. Besides, overall similarity of E1 proteins derived from 
different HPVs is not high, and therefore a unique E1 antibody is needed for each HPV, which 
makes the research very expensive.  
We decided to introduce the universal epitope (HA-tag) into genomes of two different HPV 
types and compare their and wtHPV replication levels. As a result, the replication patterns of 
the new HPV genomes were similar to those of wtHPVs in the U2OS cell line suggesting that 
compared with wtE1, HA-tagged E1 is similarly expressed and has a similar biological activity. 
The HA-tag is a peptide derived from Human influenza virus. It can be used as an epitope for 
many commercially available HA-tag specific antibodies. The amino acid sequence of the HA-
tag is YPYDVPDYA. Cloning of the HA-tag encoding sequence into E1 ORF of HPV11 and 
HPV18 provides various possibilities of using E1-HA HPV11/HPV18 constructs in studies on 
the functions of E1 protein. We can detect the levels and possible post-translational 
modifications of biologically active HA-tagged E1 protein at different stages of viral replication 
using specific HA-tag antibodies. Also, we can detect and analyze E1 binding proteins using 
the co-immunoprecipitation technique. The HA-tag can be cloned into E1 ORFs of other HPV 
types, generating universal possibility for detecting E1 proteins in different replicating viruses 
using HA-tag antibodies. 
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CONCLUSION 
Encoded by HPVs the E1 protein is one of the best targets for the development of new antiviral 
drugs. The goal of this study is to generate new HPV11 and HPV18 constructs by cloning the 
HA-tag encoding sequence in the E1 ORF with subsequent testing of their replication ability in 
human osteosarcoma cell line U2OS. These constructs will help in studies of E1 protein-
associated processes, since HA-tag can be used as an epitope for many commercially available 
HA-tag specific antibodies. The high-risk oncogenic HPV18 and low-risk HPV11 used in the 
present study belong to mucosal types of Alphapapillomavirus genus. The HA-tag encoding 
sequence was cloned in their E1 ORFs after the 15th nucleotide starting from ATG codon. 
First of all, the HA-tag encoding sequence was introduced by the PCR technology into HPV11 
and HPV18 DNA fragments, and the obtained fragments were cloned into parental HPV 
genomes. The resulted constructs were amplified in bacteria, and mutated HPV genomes were 
generated using the minicircle DNA technology (Kay et al., 2010). Among 10 analyzed clones, 
only one clone of E1-HA HPV11 was ligated correctly; in the case of E1-HA HPV18, the 
success rate was two correct clones out of 16 analyzed. Finally, I had fully workable HPV11 
and HPV18 E1-HA constructs. 
An extrinsical sequence cloned into protein can change its structure and destroy its biological 
activity. E1 helicase is essential for HPV replication; so I controlled E1-HA HPV11 and E1-
HA HPV18 replication ability in U2OS cells and compared their replication intensity with 
wtHPV11 and wtHPV18 using the Southern Blot method. Replication of different types of 
HPVs in the U2OS cell line varies greatly, and some of them like HPV11 replicate more 
intensively than others like HPV18. During the analysis of the replication status of HPVs in the 
U2OS cell line, I found that the replication of the mutated and wtHPV genomes was similar. 
The latter indicates that HA-tagged E1 proteins were active. 
The obtained E1-HA HPV constructs open a new cost-effective direction in study of E1-
associated processes, especially in replication of HPVs. Potentially, the HA-tag encoding 
sequence can also be cloned into E1 ORFs of other HPVs, and HA-tag specific antibodies can 
be used in HPV research.  
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Inimese papilloomiviiruse tüüp 11 ja 18 hemaglutiniin märgisega E1 lugemisraami 
kodeerivate genoomide kloneerimine ja analüüs 
Viktor Levin 
RESÜMEE 
Inimese papilloomiviirused (HPV) on laialt levinud populatsioonis ja nad esinevad ka 
normaalse naha mikrobiootas (Hazard et al., 2007). Nad nakatavad epiteelkoe keratinotsüüte 
mikrokahjustuse kaudu. Peamine põhjus uurida HPV-d on nende seos vähkkasvajatega, 
sealhulgas anogenitaal-, pea- ja kaelapiirkonna seotud kasvajatega (Adams et al., 2004). HPV 
elutsükli parem mõistmine aitab leida uusi meetodeid HPV-seotud haiguseid vältimiseks või 
ravimiks. 
E1 valk on üks parimaid sihtmärke viirusevastaste ravimite arendamiseks. E1 valgul on 
erinevaid ülesandeid HPV infekstiooni jooksul, kuid E1 põhiülesanne on osaleda HPV DNA 
replikatsioonil (Bergvall et al., 2013). E1 ja E2 on ainsad HPV valgud, mis on vajalikud ja 
piisavad HPV replikatsiooniks ja pärssides nende aktiivsust on hea võimalus HPV infektsiooni 
inhibeerimiseks (Yang et al., 1993). E1 valgu tuvastamine ja puhastamine on suur probleem ja 
seetõttu on E1-seotud protsesside uurimine ja E1valgu vastu uute ravimite väljatöötamine ka 
keeruline. 
Minu uuringu eesmärk on luua uued HPV11 ja HPV18 genoomide konstruktid koos HA-
märgist kodeerivat järjestusega E1 lugemisraami sees ja nende replikatsiooni võime 
kontrollimine inimese osteosarkoomi U2OS rakuliinis. Esiteks kloonisin HA-märgist 
kodeerivad järjestused HPV11 ja HPV18 E1 lugemisraami ja seejärel kloonisin saadud 
fragmendid HPV genoomidesse. Saadud konstruktid paljundasin bakterites ja sain vastavad 
mutantsed genoomid pisirõngas DNA tehnoloogia abil (Kay et al., 2010). E1 helikaas on vajalik 
HPV replikatsiooniks ja seega kontrollisin E1-HA HPV11 ja E1-HA HPV18 
replikatsioonivõimet võrreldes metsik-tüüpi HPV11 ja HPV18 replikatsiooniga U2OS 
rakuliinis. E1-HA HPV konstruktide replikatsioon on võrreldav metsik-tüüpi HPV 
replikatsiooniga ja see tähendab, et HA-märgisega E1 valk on funktsionaalne.  
Saadud E1-HA HPV konstruktid avavad uusi võimalusi E1 valguga seotud protsesside, eriti 
HPV-de replikatsiooni, uurimiseks.  Potentsiaalselt on HA-märgist kodeerivat järjestust ka 
võimalik kloonida teiste HPV-de E1 lugemisraamide sisse ja HA-märgise vastaseid antikehi on 
võimalik laialt kasutada HPV uurimiseks. See töö on tehtud Tehnoloogiainstituudi 
molekulaarse viroloogia rühmas Tartu Ülikoolis. 
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